Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer

Advanced Drug Delivery Reviews

Volumn 57, Issue 4 SPEC.ISS., 2005, Pages 579-596

  Wadia, Jehangir S ^a   Dowdy, Steven F ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Cancer; HIV1 TAT; Peptide therapy; Protein therapy; Protein transduction

Indexed keywords

CELL MEMBRANES; DRUG DOSAGE; GENE TRANSFER; MACROMOLECULES; TISSUE; TOXIC MATERIALS;

EUKARYOTIC CELLS; GENETIC DISORDERS; PHARMACOLOGICAL AGENTS; PLASMA MEMBRANES;

PROTEINS;

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEPARIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MERLIN; PHOSPHOLIPASE C GAMMA; PROTEIN BCL 2; PROTEIN P16INK4A; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN S 100; PROTEIN VP22; RETINOBLASTOMA PROTEIN; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; VIRUS VECTOR; VON HIPPEL LINDAU PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; APOPTOSIS; CANCER; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE PERMEABILITY; CELL SURFACE; CELL TRANSPORT; DNA BINDING; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENDOSOME; EXPRESSION VECTOR; GENE EXPRESSION SYSTEM; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; KIDNEY CARCINOMA; LIP; MITOSIS INHIBITION; MOLECULAR MECHANICS; NEURILEMOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY TUMOR; PEPTIDE MAPPING; PINOCYTOSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RETINOBLASTOMA; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 13844256697     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2004.10.005     Document Type: Review

References (121)

1. E.S.o.G. Therapy French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID) J. Gene Med. 5 2003 82 84
2. T. Reid, R. Warren, and D. Kirn Intravascular adenoviral agents in cancer patients: lessons from clinical trials Cancer Gene Ther. 9 2002 979 986
3. R. Vile, D. Ando, and D. Kirn The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider Cancer Gene Ther. 9 2002 1062 1067
4. J.S. Wadia, and S.F. Dowdy Protein transduction technology Curr. Opin. Biotechnol. 13 2002 52 56
5. J.S. Wadia, and S.F. Dowdy Modulation of cellular function by TAT mediated transduction of full length proteins Curr. Protein Pept. Sci. 4 2003 97 104
6. W. Anderson Human gene therapy Nature 392 1998 25 30
7. P.P. Ng, J.S. Dela Cruz, D.N. Sorour, J.M. Stinebaugh, S.U. Shin, D.S. Shin, S.L. Morrison, and M.L. Penichet An anti traferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells Proc. Natl. Acad. Sci. U. S. A. 99 2002 10706 10711
8. Y. Abu-Amer, S.F. Dowdy, F.P. Ross, J.C. Clohisy, and S.L. Teitelbaum TAT fusion proteins containing tyrosine 42-deleted IkappaBalpha arrest osteoclastogenesis J. Biol. Chem. 276 2001 30499 30503
9. A. Joliot, C. Pernelle, H. Deagostini-Bazin, and A. Prochiantz Antennapedia homeobox peptide regulates neural morphogenesis Proc. Natl. Acad. Sci. U. S. A. 88 1991 1864 1868
10. A. Joliot, A. Triller, M. Volovitch, C. Pernelle, and A. Prochiantz Alpha-2-8-polysialic acid is the neuronal surface receptor of antennapedia homeobox peptide New Biol. 3 1991 1121 1134
11. I. Le Roux, A.H. Joliot, E. Bloch-Gallego, A. Prochiantz, and M. Volovitch Neurotrophic activity of the Antennapedia homeodomain depends on its specific DNA-binding properties Proc. Natl. Acad. Sci. U. S. A. 90 1993 9120 9124
12. G. Elliott, and P. O'Hare Intercellular trafficking and protein delivery by a herpesvirus structural protein Cell 88 1997 223 233
13. M. Green, and P. Loewenstein Autonomous functional domains of chemically synthesized human immunodeficiency virus Tat trans-activator protein Cell 55 1988 1179 1188
14. A. Frankel, and C. Pabo Cellular uptake of the Tat protein from human immunodeficiency virus Cell 55 1988 1189 1193
15. S. Fawell, J. Seery, Y. Daikh, C. Moore, L. Chen, B. Pepinsky, and J. Barsoum Tat-mediated delivery of heterologous proteins into cells Proc. Natl. Acad. Sci. U. S. A. 91 1994 664 668
16. D. Mann, and A. Frankel Endocytosis and targeting of exogenous HIV-1 Tat protein EMBO J. 10 1991 1733 1739
17. H. Nagahara, A.M. Vocero-Akbani, E.L. Snyder, A. Ho, D.G. Latham, N.A. Lissy, M. Becker-Hapak, S.A. Ezhevsky, and S.F. Dowdy Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration Nat. Med. 4 1998 1449 1452
18. A. Astriab-Fisher, D. Sergueev, M. Fisher, B.R. Shaw, and R.L. Juliano Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions Pharm. Res. 19 2002 744 754
19. V. Polyakov, V. Sharma, J.L. Dahlheimer, C.M. Pica, G.D. Luker, and D. Piwnica-Worms Novel Tat-peptide chelates for direct transduction of technetium-99m and rhenium into human cells for imaging and radiotherapy Bioconjug. Chem. 11 2000 762 771
20. C.H. Dodd, H.C. Hsu, W.J. Chu, P. Yang, H.G. Zhang, J.D. Mountz Jr., K. Zinn, J. Forder, L. Josephson, R. Weissleder, J.M. Mountz, and J.D. Mountz Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles J. Immunol. Methods 256 2001 89 105
21. P. Wunderbaldinger, L. Josephson, and R. Weissleder Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles Bioconjug. Chem. 13 2002 264 268
22. M. Lewin, N. Carlesso, C.H. Tung, X.W. Tang, D. Cory, D.T. Scadden, and R. Weissleder Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells Nat. Biotechnol. 18 2000 410 414
23. L. Josephson, C.H. Tung, A. Moore, and R. Weissleder High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates Bioconjug. Chem. 10 1999 186 191
24. T. Barka, E. Gresik, and H. van der Noen Transduction of TAT-HA-b-galactosidase fusion protein into salivary gland-derived cells and organ cultures of the developing gland, and into rat submandibular gland in vivo J. Histochem. Cytochem. 48 2000 1453 1460
25. J. Sodroski, R. Patarca, C. Rosen, F. Wong-Staal, and W. Haseltine Location of the trans-activating region on the genome of human T-cell lymphotrophic virus type III Science 229 1985 74 77
26. J. Sodroski, C. Rosen, F. Wong-Staal, S. Salahuddin, M. Popovic, S. Arya, R. Gallo, and W. Haseltine Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat Science 227 1985 171 173
27. S. Ruben, A. Perkins, R. Purcell, K. Joung, R. Sia, R. Burghoff, W. Haseltine, and C. Rosen Structural and functional characterization of human immunodeficiency virus Tat protein J. Virol. 63 1989 1 8
28. P. McNeil, R. Murphy, F. Lanni, and D. Taylor A method for incorporating macromolecules into adherent cells J. Cell Biol. 98 1984 1556 1564
29. M.B. Feinberg, D. Baltimore, and A.D. Frankel The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation Proc. Natl. Acad. Sci. U. S. A. 88 1991 4045 4049
30. M. Tyagi, M. Rusnati, M. Presta, and M. Giacca Internalization of HIV-1 requires cell surface heparan sulfate proteoglycans JBC 276 2001 3254 3261
31. S. Hakansson, A. Jacobs, and M. Caffrey Heparin binding by the HIV-1 tat protein transduction domain Protein Sci. 10 2001 2138 2139
32. E. Vives, P. Brodin, and B. Lebleu A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus JBC 272 1997 16010 16017
33. F. Perez, A. Joliot, E. Bloch-Gallego, A. Zahraoui, A. Triller, and A. Prochiantz Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide J. Cell. Sci. 102 Pt 4 1992 717 722
34. K. Fujimoto, R. Hosotani, Y. Miyamoto, R. Doi, T. Koshiba, A. Otaka, N. Fujii, R.D. Beauchamp, and M. Imamura Inhibition of pRb phosphorylation and cell cycle progression by an antennapedia-p16(INK4A) fusion peptide in pancreatic cancer cells Cancer Lett. 159 2000 151 158
35. P.E. Thoren, D. Persson, M. Karlsson, and B. Norden The antennapedia peptide penetratin translocates across lipid bilayers-the first direct observation FEBS Lett. 482 2000 265 268
36. A. Phelan, G. Elliot, and P. O'Hare Intercellular delivery of functional p53 by the herpesvirus protein VP22 Nat. Biotechnol. 16 1998 440 443
37. G. Elliott, and P. O'Hare Intercellular trafficking of VP22-GFP fusion proteins Gene Ther. 6 1999 149 151
38. N. Brewis, A. Phelan, J. Webb, J. Drew, G. Elliott, and P. O'Hare Evaluation of VP22 spread in tissue culture J. Virol. 74 2000 1051 1056
39. S. Uemura, J.B. Rothbard, H. Matsushita, P.S. Tsao, C.G. Fathman, and J.P. Cooke Short polymers of arginine rapidly translocate into vascular cells Circ. J. 66 2002 1155 1160
40. P.A. Wender, J.B. Rothbard, T.C. Jessop, E.L. Kreider, and B.L. Wylie Oligocarbamate molecular transporters: design, synthesis, and biological evaluation of a new class of transporters for drug delivery J. Am. Chem. Soc. 124 2002 13382 13383
41. J.B. Rothbard, E. Kreider, C.L. VanDeusen, L. Wright, B.L. Wylie, and P.A. Wender Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake J. Med. Chem. 45 2002 3612 3618
42. S. Futaki, T. Suzuki, W. Ohashi, T. Yagami, S. Tanaka, K. Ueda, and Y. Sugiura Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery J. Biol. Chem. 276 2001 5836 5840
43. P.A. Wender, D.J. Mitchell, K. Pattabiraman, E.T. Pelkey, L. Steinman, and J.B. Rothbard The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters Proc. Natl. Acad. Sci. U. S. A. 97 2000 13003 13008
44. D. Kato, K. Miyazawa, M. Ruas, M. Starborg, I. Wada, T. Oka, T. Sakai, G. Peters, and E. Hara Features of replicative senescence induced by direct addition of antennapedia-p16INK4A fusion protein to human diploid fibroblasts FEBS Lett. 427 1998 203 208
45. Y.N. Chen, S.K. Sharma, T.M. Ramsey, L. Jiang, M.S. Martin, K. Baker, P.D. Adams, K.W. Bair, and W.G. Kaelin Jr. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists Proc. Natl. Acad. Sci. U. S. A. 96 1999 4325 4329
46. M. Becker-Hapak, S.S. McAllister, and S.F. Dowdy TAT-mediated protein transduction into mammalian cells Methods 24 2001 247 256
47. S.R. Schwarze, A. Ho, A. Vocero-Akbani, and S.F. Dowdy In vivo protein transduction: delivery of a biologically active protein into the mouse Science 285 1999 1569 1572
48. A.M. Vocero-Akbani, N.V. Heyden, N.A. Lissy, L. Ratner, and S.F. Dowdy Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein Nat. Med. 5 1999 29 33
49. N.J. Caron, Y. Torrente, G. Camirand, M. Bujold, P. Chapdelaine, K. Leriche, N. Bresolin, and J.P. Tremblay Intracellular delivery of a Tat-eGFP fusion protein into muscle cells Molec. Ther. 3 2001 310 318
50. K. Han, M.J. Jeon, S.H. Kim, D. Ki, J.H. Bahn, K.S. Lee, J. Park, and S.Y. Choi Efficient intracellular delivery of an exogenous protein GFP with genetically fused basic oligopeptides Mol. Cells 12 2001 267 271
51. S.K. Joshi, K. Hashimoto, and P.A. Koni Induced DNA recombination by Cre recombinase protein transduction Genesis 33 2002 48 54
52. M. Peitz, K. Pfannkuche, K. Rajewsky, and F. Edenhofer Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: a tool for efficient genetic engineering of mammalian genomes Proc. Natl. Acad. Sci. U. S. A. 99 2002 4489 4494
53. N.A. Lissy, L.F. Van Dyk, M. Becker-Hapak, A. Vocero-Akbani, J.H. Mendler, and S.F. Dowdy TCR antigen-induced cell death occurs from a late G1 phase cell cycle check point Immunity 8 1998 57 65
54. N.A. Lissy, P.K. Davis, M. Irwin, W.G. Kaelin, and S.F. Dowdy A common E2F-1 and p73 pathway mediates cell death induced by TCR activation Nature 407 2000 642 645
55. D.J. Mitchell, D.T. Kim, L. Steinman, C.G. Fathman, and J.B. Rothbard Polyarginine enters cells more efficiently than other polycationic homopolymers J. Pept. Res. 56 2000 318 325
56. M. Rusnati, G. Tulipano, C. Urbinati, E. Tanghetti, R. Giuliani, M. Giacca, M. Ciomei, A. Corallini, and M. Presta The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists J. Biol. Chem. 273 1998 16027 16037
57. M. Rusnati, D. Coltrini, P. Oreste, G. Zoppetti, A. Albini, D. Noonan, F. di Fagagna, M. Giacca, and M. Presta Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size J. Biol. Chem. 272 1997 11313 11320
58. M. Lundberg, and M. Johansson Positively charged DNA-binding proteins cause apparent cell membrane translocation Biochem. Biophys. Res. Commun. 291 2002 367 371
59. E. Vives, J.P. Richard, C. Rispal, and B. Lebleu TAT peptide internalization: seeking the mechanism of entry Curr. Protein Pept. Sci. 4 2003 125 132
60. J.S. Wadia, R.V. Stan, and S.F. Dowdy Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis Nat. Med. 10 2004 310 315
61. S.D. Conner, and S.L. Schmid Regulated portals of entry into the cell Nature 422 2003 37 44
62. M. Silhol, M. Tyagi, M. Giacca, B. Lebleu, and E. Vives Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat Eur. J. Biochem. 269 2002 494 501
63. S. Console, C. Marty, C. Garcia-Echeverria, R. Schwendener, and K. Ballmer-Hofer Antennapedia and HIV TAT 'protein transduction domains' promote endocytosis of high Mr cargo upon binding to cell surface glycosaminoglycans J. Biol. Chem. 2003
64. M. Lundberg, S. Wikstrom, and M. Johansson Cell surface adherence and endocytosis of protein transduction domains Molec. Ther. 8 2003 143 150
65. A. Fittipaldi, A. Ferrari, M. Zoppe, C. Arcangeli, V. Pellegrini, F. Beltram, and M. Giacca Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 tat fusion proteins J. Biol. Chem. 278 2003 34141 34149
66. O. Meier, K. Boucke, S.V. Hammer, S. Keller, R.P. Stidwill, S. Hemmi, and U.F. Greber Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake J. Cell Biol. 158 2002 1119 1131
67. C.C. Norbury, L.J. Hewlett, A.R. Prescott, N. Shastri, and C. Watts Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages Immunity 3 1995 783 791
68. D. Jo, A. Nashabi, C. Doxsee, Q. Lin, D. Unutmaz, J. Chen, and H.E. Ruley Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase Nat. Biotechnol. 19 2001 929 933
69. H. Xia, Q. Mao, and B.L. Davidson The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors Nat. Biotechnol. 19 2001 640 644
70. C.J. Sherr, and F. McCormick The RB and p53 pathways in cancer Cancer Cell 2 2002 103 112
71. T.R. Hupp, A. Sparks, and D.P. Lane Small peptides activate the latent sequence-specific DNA binding function of p53 Cell 83 1995 237 245
72. G. Selivanova, V. Iotsova, I. Okan, M. Fritsche, M. Strom, B. Groner, R.C. Grafstrom, and K.G. Wiman Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain Nat. Med. 3 1997 632 638
73. J.W. Harbour, L. Worley, D. Ma, and M. Cohen Transducible peptide therapy for uveal melanoma and retinoblastoma Arch. Ophthalmol. 120 2002 1341 1346
74. X. Wu, J.H. Bayle, D. Olson, and A.J. Levine The p53-mdm-2 autoregulatory feedback loop Genes Dev. 7 1993 1126 1132
75. E.L. Snyder, B.R. Meade, C.C. Saenz, and S.F. Dowdy Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide PLoS Biol. 2 2004 E36
76. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
77. A. Ho, and S.F. Dowdy Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes Curr. Opin. Genet. Dev. 12 2002 47 52
78. C.J. Sherr, and J.M. Roberts CDK inhibitors: positive and negative regulators of G1-phase progression Genes Dev. 13 1999 1501 1512
79. M.H. Lee, and H.Y. Yang Negative regulators of cyclin-dependent kinases and their roles in cancers Cell. Mol. Life Sci. 58 2001 1907 1922
80. C.J. Sherr The INK4a/ARF network in tumour suppression Nat. Rev., Mol. Cell Biol. 2 2001 731 737
81. G.I. Shapiro, C.D. Edwards, and B.J. Rollins The physiology of p16(INK4A)-mediated G1 proliferative arrest Cell Biochem. Biophys. 33 2000 189 197
82. M. Ruas, S. Brookes, N.Q. McDonald, and G. Peters Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information Oncogene 18 1999 5423 5434
83. J.W. Rocco, and D. Sidransky p16(MTS-1/CDKN2/INK4a) in cancer progression Exp. Cell Res. 264 2001 42 55
84. R. Fahraeus, J.M. Paramio, K.L. Ball, S. Lain, and D.P. Lane Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A Curr. Biol. 6 1996 84 91
85. D.R. Gius, S.A. Ezhevsky, M. Becker-Hapak, H. Nagahara, M.C. Wei, and S.F. Dowdy Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1 Cancer Res. 59 1999 2577 2580
86. S.A. Ezhevsky, H. Nagahara, A.M. Vocero-Akbani, D.R. Gius, M.C. Wei, and S.F. Dowdy Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb Proc. Natl. Acad. Sci. U. S. A. 94 1997 10699 10704
87. W.S. el-Deiry, J.W. Harper, P.M. O'Connor, V.E. Velculescu, C.E. Canman, J. Jackman, J.A. Pietenpol, M. Burrell, D.E. Hill, and Y. Wang WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis Cancer Res. 54 1994 1169 1174
88. K.L. Ball, S. Lain, R. Fahraeus, C. Smythe, and D.P. Lane Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1 Curr. Biol. 7 1997 71 80
89. M. Bonfanti, S. Taverna, M. Salmona, M. D'Incalci, and M. Broggini p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth Cancer Res. 57 1997 1442 1446
90. E.L. Snyder, B.R. Meade, and S.F. Dowdy Anti-cancer protein transduction strategies: reconstitution of p27 tumor suppressor function J. Control. Release 91 2003 45 51
91. Y. Parada, L. Banerji, J. Glassford, N.C. Lea, M. Collado, C. Rivas, J.L. Lewis, M.Y. Gordon, N.S. Thomas, and E.W. Lam BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression J. Biol. Chem. 276 2001 23572 23580
92. S.A. Ezhevsky, A. Ho, M. Becker-Hapak, P.K. Davis, and S.F. Dowdy Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo Mol. Cell. Biol. 21 2001 4773 4784
93. M.V. Blagosklonny, and A.B. Pardee Exploiting cancer cell cycling for selective protection of normal cells Cancer Res. 61 2001 4301 4305
94. W. Krek, M.E. Ewen, S. Shirodkar, Z. Arany, W.G. Kaelin Jr., and D.M. Livingston Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase Cell 78 1994 161 172
95. Y.N. Chen, S.K. Sharma, T.M. Ramsey, L. Jiang, M.S. Martin, K. Baker, P.D. Adams, K.W. Bair, and W.G. Kaelin Jr. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists Proc. Natl. Acad. Sci. U. S. A. 96 1999 4325 4329
96. S. Ortega, M. Malumbres, and M. Barbacid Cyclin D-dependent kinases, INK4 inhibitors and cancer Biochim. Biophys. Acta 1602 2002 73 87
97. Y.L. Yang, and X.M. Li The IAP family: endogenous caspase inhibitors with multiple biological activities Cell Res. 10 2000 169 177
98. M. Holcik, H. Gibson, and R.G. Korneluk XIAP: apoptotic brake and promising therapeutic target Apoptosis 6 2001 253 261
99. Y. Shi Mechanisms of caspase activation and inhibition during apoptosis Mol. Cell 9 2002 459 470
100. C.R. Arnt, M.V. Chiorean, M.P. Heldebrant, G.J. Gores, and S.H. Kaufmann Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ J. Biol. Chem. 277 2002 44236 44243
101. S. Fulda, W. Wick, M. Weller, and K.M. Debatin Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo Nat. Med. 8 2002 808 815
102. L. Yang, T. Mashima, S. Sato, M. Mochizuki, H. Sakamoto, T. Yamori, T. Oh-Hara, and T. Tsuruo Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide Cancer Res. 63 2003 831 837
103. A. Gross, J.M. McDonnell, and S.J. Korsmeyer BCL-2 family members and the mitochondria in apoptosis Genes Dev. 13 1999 1899 1911
104. R.J. Lutz Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins Biochem. Soc. Trans. 28 2000 51 56
105. E.P. Holinger, T. Chittenden, and R.J. Lutz Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases J. Biol. Chem. 274 1999 13298 13304
106. A. Letai, M.C. Bassik, L.D. Walensky, M.D. Sorcinelli, S. Weiler, and S.J. Korsmeyer Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics Cancer Cell 2 2002 183 192
107. H.C. Chang, F. Samaniego, B.C. Nair, L. Buonaguro, and B. Ensoli HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region Aids 11 1997 1421 1431
108. S. Asada, Y. Choi, M. Yamada, S.C. Wang, M.C. Hung, J. Qin, and M. Uesugi External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator Proc. Natl. Acad. Sci. U. S. A. 99 2002 12747 12752
109. B. Zbar, G. Glenn, I. Lubensky, P. Choyke, M.M. Walther, G. Magnusson, U.S. Bergerheim, S. Pettersson, M. Amin, and K. Hurley Hereditary papillary renal cell carcinoma: clinical studies in 10 families J. Urol. 153 1995 907 912
110. K. Datta, R. Nambudripad, S. Pal, M. Zhou, H.T. Cohen, and D. Mukhopadhyay Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer J. Biol. Chem. 275 2000 20700 20706
111. K. Datta, C. Sundberg, S.A. Karumanchi, and D. Mukhopadhyay The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion Cancer Res. 61 2001 1768 1775
112. H.E. Ryan, J. Lo, and R.S. Johnson HIF-1 alpha is required for solid tumor formation and embryonic vascularization EMBO J. 17 1998 3005 3015
113. A.Y. Yu, M.G. Frid, L.A. Shimoda, C.M. Wiener, K. Stenmark, and G.L. Semenza Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung Am. J. Physiol. 275 1998 L818 L826
114. L.E. Huang, J. Gu, M. Schau, and H.F. Bunn Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway Proc. Natl. Acad. Sci. U. S. A. 95 1998 7987 7992
115. H. Harada, M. Hiraoka, and S. Kizaka-Kondoh Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells Cancer Res. 62 2002 2013 2018
116. P. Merel, K. Hoang-Xuan, M. Sanson, A. Moreau-Aubry, E.K. Bijlsma, C. Lazaro, J.P. Moisan, F. Resche, I. Nishisho, and X. Estivill Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas Genes, Chromosomes Cancer 13 1995 211 216
117. A.M. Bashour, J.J. Meng, W. Ip, M. MacCollin, and N. Ratner The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human schwannoma cells Mol. Cell. Biol. 22 2002 1150 1157
118. R. Donato Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type Biochim. Biophys. Acta 1450 1999 191 231
119. E. Makino, M. Sakaguchi, K. Iwatsuki, and N.H. Huh Introduction of an N-terminal peptide of S100C/A11 into human cells induces apoptotic cell death J. Mol. Med. 2004
120. N. Shibagaki, and M.C. Udey Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity J. Immunol. 168 2002 2393 2401
121. Y. Katterle, B.H. Brandt, S.F. Dowdy, B. Niggemann, K.S. Zanker, and T. Dittmar Antitumour effects of PLC-gamma1-(SH2)2-TAT fusion proteins on EGFR/c-erbB-2-positive breast cancer cells Br. J. Cancer 90 2004 230 235